Browsing Tag
EVT801
2 posts
Kazia Therapeutics (NASDAQ: KZIA) bets on SETDB1 to widen oncology pipeline beyond paxalisib
Kazia Therapeutics has licensed a SETDB1 oncology platform from QIMR Berghofer. Read why the move could reshape KZIA’s pipeline strategy.
Kazia Therapeutics (NASDAQ: KZIA) unveils immune-boosting effects of paxalisib in advanced breast cancer at SABCS 2025
Find out how Kazia Therapeutics’ paxalisib is breaking new ground in breast cancer immunotherapy. Read the latest clinical insights from SABCS 2025.